Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pedi-EVOLVE
NCT07568509Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of norethisterone acetate and ethinyl estradiol in Oxytocin deficiency (2 cohorts), sponsored by Massachusetts General Hospital. Primary endpoint: Change in neurophysin-1 from baseline at 24 hours. Started Aug 2026; status: recruiting.
02
Drugs
norethisterone acetateethinyl estradiol
03
Conditions
Oxytocin deficiency
Beyond the preview
Go deeper on NCT07568509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568509.